Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases: Guidance for Industry; Availability
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
August 8, 2024
August 9, 2024
65250af0-1be1-43c2-bace-d1002014248b
Related Documents
Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment: Guidance for Industry; Availability
Guidance DocumentOctober 17, 2022Office of the Commissioner
Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment: Guidance for Industry
Guidance DocumentJanuary 24, 2020Center for Drug Evaluation and Research
Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials
Guidance DocumentMarch 13, 2019Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox